Find a Clinical Trial

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)

A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)

18+

Learn more

Evaluation of BE1116 (4F-PCC) in patients with traumatic injury and confirmed or suspected acute major bleeding to improve survival

A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled,Large Simple Trial Evaluating the Use of BE1116 (4-Factor Prothrombin Complex Concentrate [Kcentra^® / Beriplex^®]) to Improve Survival in Patients with Traumatic Injury and Confirmed or Suspected Acute Major Bleeding Predicted to Receive a Large Volume Blood Product Transfusion

15+

Learn more

Feasibility of a new method for non-invasive monitoring of low-grade bladder cancer

Feasibility of a new method for non-invasive monitoring of low-grade bladder cancer

18-90

Learn more